Skip to content
Open access

Exploring the immunotherapeutic potential of Vγ9Vδ2-T cells in cancer using bispecific antibodies

Abstract

Bispecific T cell engagers (bsTCEs) are engineered antibodies designed to simultaneously bind a tumor-associated antigen (TAA) and, most commonly, the CD3 complex on T cells. By bridging tumor and effector cells, bsTCEs promote the formation of an immunological synapse that triggers potent cytotoxic responses, bypassing the need for MHC-restricted T cell recognition. An increasing number of CD3-based bsTCEs have demonstrated clinical success in hematological malignancies; however, their efficacy in solid tumors remains limited. Major barriers to broader clinical application include the immunosuppressive tumor microenvironment (TME) of solid tumors, limited tumor selectivity resulting in on-target/off-tumor toxicity, and systemic toxicities, most notably cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. In this thesis, we investigate the preclinical potential of bsTCEs that selectively engage innate-like T-cell subsets, including type 1 NKT cells and Vγ9Vδ2-T cells, rather than broadly activating all CD3⁺ T cells, with the aim of combining potent anti-tumor activity with reduced toxicity. The thesis describes the generation and antitumor potential of 5T4- and CD1d-directed Vδ2-bsTCEs, explores expression of 5T4 and CD1d across solid tumors, and evaluates strategies to promote Vγ9Vδ2-T cell expansion, including the use of Vδ2-bsTCEs with bivalent Vδ2-TCR binding and combination treatment of the CD1d-Vδ2 bsTCE with the immunomodulatory drug lenalidomide. Together, this work provides a preclinical framework for the development of Vγ9Vδ2-T cell-redirecting bsTCEs to treat solid (and hematological) tumors and highlights future directions for the development of γδ-T cell-redirecting therapies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.